- Home
- PLX vs AVX Comparison
PLX vs AVX Comparison
Compare PLX & AVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PLX | AVX |
|---|---|---|
| Founded | 1993 | 2017 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Metal Fabrications |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 142.3M | 119.2M |
| IPO Year | 1998 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PLX | AVX |
|---|---|---|
| Price | $1.79 | $1.77 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $12.00 | N/A |
| AVG Volume (30 Days) | ★ 586.0K | 140.4K |
| Earning Date | 11-13-2025 | 03-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.07 | N/A |
| Revenue | ★ $61,840,000.00 | $1,319,011.00 |
| Revenue This Year | $14.29 | $530,767.50 |
| Revenue Next Year | $16.65 | N/A |
| P/E Ratio | $25.77 | ★ N/A |
| Revenue Growth | 35.41 | ★ 8001.54 |
| 52 Week Low | $1.32 | $1.12 |
| 52 Week High | $3.10 | $25.38 |
Technical Indicators
Market Signals| Indicator | PLX | AVX |
|---|---|---|
| Relative Strength Index (RSI) | 47.81 | N/A |
| Support Level | $1.72 | N/A |
| Resistance Level | $1.84 | N/A |
| Average True Range (ATR) | 0.08 | 0.00 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 41.38 | 0.00 |
Price Performance
Historical ComparisonAbout PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
About AVX Avax One Technology Ltd.
AVAX One Technology Ltd is a public company offering investors regulated access to the Avalanche (AVAX) ecosystem. By integrating the reliability of U.S. capital markets with the growth potential of decentralized finance, it seeks to create a bridge between traditional and digital finance. The company focuses on building a digital-asset treasury, fostering innovation, and investing in decentralized financial technologies that benefit from the Avalanche network.